ADMA Biologics Inc (ADMA) Expected to Announce Earnings of -$0.35 Per Share
Wall Street brokerages forecast that ADMA Biologics Inc (NASDAQ:ADMA) will post earnings of ($0.35) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for ADMA Biologics’ earnings, with estimates ranging from ($0.39) to ($0.31). ADMA Biologics posted earnings per share of ($0.55) in the same quarter last year, which would suggest a positive year over year growth rate of 36.4%. The firm is scheduled to issue its next earnings results on Friday, August 10th.
According to Zacks, analysts expect that ADMA Biologics will report full-year earnings of ($1.35) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($1.24). For the next year, analysts anticipate that the business will post earnings of ($0.23) per share, with EPS estimates ranging from ($0.36) to $0.00. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for ADMA Biologics.
ADMA has been the topic of a number of research analyst reports. Maxim Group set a $8.00 price target on ADMA Biologics and gave the stock a “buy” rating in a report on Monday, March 5th. ValuEngine raised ADMA Biologics from a “strong sell” rating to a “sell” rating in a report on Saturday, April 7th. Finally, LADENBURG THALM/SH SH lowered their price target on ADMA Biologics to $7.50 and set a “buy” rating on the stock in a report on Wednesday.
In other news, CEO Adam S. Grossman acquired 52,301 shares of the firm’s stock in a transaction dated Friday, June 8th. The shares were acquired at an average cost of $4.78 per share, with a total value of $249,998.78. Following the acquisition, the chief executive officer now directly owns 32,527 shares of the company’s stock, valued at $155,479.06. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Jerrold B. Grossman acquired 20,921 shares of the firm’s stock in a transaction dated Friday, June 8th. The shares were purchased at an average cost of $4.78 per share, for a total transaction of $100,002.38. Following the completion of the acquisition, the director now directly owns 98,007 shares in the company, valued at $468,473.46. The disclosure for this purchase can be found here. Insiders have bought a total of 78,222 shares of company stock worth $373,901 over the last ninety days. Insiders own 16.90% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of ADMA Biologics by 59.5% during the 1st quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock worth $186,000 after acquiring an additional 15,115 shares in the last quarter. Spark Investment Management LLC purchased a new stake in shares of ADMA Biologics during the 1st quarter worth approximately $102,000. Element Capital Management LLC purchased a new stake in shares of ADMA Biologics during the 1st quarter worth approximately $118,000. Iguana Healthcare Management LLC increased its position in shares of ADMA Biologics by 6.2% during the 4th quarter. Iguana Healthcare Management LLC now owns 600,000 shares of the biotechnology company’s stock valued at $1,926,000 after purchasing an additional 35,000 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in shares of ADMA Biologics during the 1st quarter valued at approximately $182,000. 37.42% of the stock is currently owned by institutional investors and hedge funds.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.